WO2006022611A2 - Creme neuropathique - Google Patents
Creme neuropathique Download PDFInfo
- Publication number
- WO2006022611A2 WO2006022611A2 PCT/US2004/020449 US2004020449W WO2006022611A2 WO 2006022611 A2 WO2006022611 A2 WO 2006022611A2 US 2004020449 W US2004020449 W US 2004020449W WO 2006022611 A2 WO2006022611 A2 WO 2006022611A2
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- weight
- transdermal composition
- gabapentin
- pain
- ketamine
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/06—Ointments; Bases therefor; Other semi-solid forms, e.g. creams, sticks, gels
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
Definitions
- the present invention relates to methods for treating or preventing pain via topical formulations that induce a local-anesthetic effect when applied to intact skin.
- Nociceptive pain is caused by noxious stimulation of nociceptors (e.g., a needle stick or skin pinch), which then transmit impulses over intact neural pathways to the spinal neurons and then to the brain.
- Neuropathic pain is caused by damage to neural structures, such as damage to peripheral nerve endings or nociceptors, which become extremely sensitive to stimulation and can generate impulses in the absence of stimulation (e.g., herpes zoster pain after the rash has healed).
- damage can be caused by a variety of means including trauma, diseases such as diabetes, herpes zoster and late-stage cancer, chemotherapy, or by a chemical injury.
- Peripheral nerve damage can lead to pathological states where there is a reduction in pain threshold (i.e., allodynia), an increased response to noxious stimuli (hyperalgesia), or an increased response duration (persistent pain).
- pain can be treated locally by topically administering a local anesthetic directly to the painful area to block the nociceptive mechanistic pathway.
- Local anesthetics prevent the generation and conduction of nociceptive nerve impulses.
- a local anesthetic can be injected intradermally (non-systemic injection within the skin) or topically applied at the pain area.
- Advantages of topical local-anesthetic administration over systemic administration of pain relievers include decrease or preclusion of side effects, improved patient compliance, and reversible action (i.e., the action can be reversed by removing the anesthetic from the application site).
- a variety of drug classes have local-anesthetic properties and can be administered in topical formulations.
- Other agents with local-anesthetic properties include analgesics, such as non-steroidal anti-inflammatories ("NSAIDs").
- NSAIDs non-steroidal anti-inflammatories
- NMDA N-methyl-D-aspartate
- ketamine have local-aesthetic properties and topical administration is as an effective neuropathic pain treatment. See, for example, U.S. Pat. No.
- topical administration of antidepressant medications has been reported effective for neuropathic pain treatment. See, for example, U.S. Pat. No. 6,211,171 (issued Apr. 3, 2001); J. Sawynok et al., 82 PAIN 149 (1999).
- topical administration of a combination of a tricyclic antidepressant and an NMDA- receptor antagonist is reported to have excellent local-anesthetic properties when topically applied and is useful for treatment of neuropathic pain, U.S. Pat. No. 6,197,830 (issued Mar. 6, 2001).
- Lecithin compositions are routinely used as bases for topical local-aesthetic compositions, but are highly oxidatively unstable (AM. PHARM. ASSOC, HANDBOOK OF PHARMACEUTICAL EXCIPIENTS 292-294, 292 (Arthur H. Kibbe ed., 3rd ed. 2000)).
- AM. PHARM. ASSOC HANDBOOK OF PHARMACEUTICAL EXCIPIENTS 292-294, 292 (Arthur H. Kibbe ed., 3rd ed. 2000)
- 4JTS. Pat No. 6, 197, 830_ issued Mar. S, 20,01 describes a lecjthin-based composition for topically administering a combination of an NMDA-receptor antagonist and a tricyclic antidepressant and U.S. Pat. Nos. 5,817,699 (issued Oct.
- topical local-anesthetic administration has advantages over systemic administration of pain relievers, they suffer from instability and poor skin-penetration properties, which limit their use to less severe pain. What are needed are stable, effective topical local-anesthetic compositions with good skin-penetration properties the avoid or reduce undesired effects such as liver damage or gastrointestinal side effects.
- the present invention provides a transdermal composition for the treatment of pain in a subject, particularly a human subject.
- a transdermal composition for the relief of pain in a subject comprising: amitriptyiline, clonidine, ketamine and an anti-inflammatory in a base.
- the amitriptyline may be between 2% and 4% by weight, preferably 4%, the clonidine between 0.2% and 0.5% by weight, preferably 0.5%.
- the composition may also have gabapentin, which may be between 5% and 15% by weight, preferably 5%.
- the ketamine may be between 5% and 20% by weight, preferably 15%.
- the anti -inflammatory may be ketoprofen between 2% and 6% by weight, preferably 5%.
- a transdermal composition for the relief of pain in a subject comprising: amitriptyiline, clonidine, gabapentin and ketamine in a base.
- the composition may also comprise 5% to 10% by weight lidocaine.
- the amitriptyline may be 2% to 4% by weight
- clonidine may be 0.2% to 0.5% by weight
- gabapentin may be 6% to 12% by weight
- a transdermal composition for the relief of pain in a subject comprising: amitriptyiline, cyclobenzaprine, dexamethazone, gabapentin and an anti-inflammatory in a base.
- the amitriptyiline may be between 2% and 4% by weight
- the cyclobenzaprine may be between 2% and 4% by weight
- the dexamethazone may be between 0.2% and 0.5% by weight
- the gabapentin may be between 6% and 12% by weight.
- the anti-inflammatory may be ibuprofen being between 18% and 22% by weight or ketoprofen being between 2% and 4% by weight.
- a transdermal composition for the relief of pain in a subject comprising: amitriptyline, cyclobenzaprine, dexamethazone, gabapentin, an anti-inflammatory and a local anesthetic in a base.
- the amitriptyline may be between 2% and 4% by weight
- the cyclobenzaprine may between 1% and 3% by weight, preferably 2%
- the dexamethazone may be between 0.3% and 0.5% by weight, preferably 0.4%.
- the gabapentin may be between 6% and 12% by weight.
- the anti ⁇ inflammatory may be between 15% by weight and 22% by weight ibuprofen, preferably 20% by weight.
- the anti-inflammatory may also be ketoprofen between 2% by weight and 4% by weight.
- the local anesthetic may be between 5% by weight and 10% by weight lidocaine.
- the local anesthetic may also be between 5% by weight and 10% by weight EMLA, preferably 7% by weight.
- a transdermal composition for the relief of pain in a subject comprising: analgesic, an anti-epileptic compound, cyclobenzaprine, gabapentin, ketamine and an local anesthetic in a base.
- the analgesic may be between 3% and 6% by weight aspirin, preferably 5% by weight.
- the anti-epileptic may be between 2% and 4% by weight carbamazepine.
- the gabapentin is preferably between 6% and 12% by weight, theJcetamine is between 13% .and 16%Jxy weight, preferably 1-5?/ ⁇ .
- the local anesthetic may be between 5% and 10% by weight lidocaine.
- a transdermal composition for the relief of pain in a subject comprising: clonidine, gabapentin, ketamine, anti-inflammatory and an local anesthetic in a base.
- the clonidine may be between 0.2% and 0.5% by weight
- the gabapentin may be between 6% and 12% by weight
- the ketamine may be between 13% and 16% by weight.
- the anti-inflammatory may be 2% to 4% by weight ketoprofen.
- the local anesthetic may be 5% to 10% by weight lidocaine or 6% to 8% by weight EMLA 1 preferably 7% by weight EMLA.
- the amitriptyline may be between 2% and 4% by weight, gabapentin may be between 6% and 12% by weight, ketamine may be between 13% and 16% by weight.
- the anti-inflammatory may be 2% to 4% by weight ketoprofen.
- the local anesthetic may be 5% to 10% by weight lidocaine or 6% to 8%, preferably 7% by weight, EMLA.
- a transdermal composition for the relief of pain in a subject comprising: 4% by weight amitriptyiline, 0.5% by weight clonidine, 15% by weight ketamine, and 5% by weight ketoprofen in a base.
- This composition may be further comprised of 5% by weight gabapentin.
- the present invention provides a transdermal composition suitable for the treatment of pain in a subject.
- This may include neuropathic pain of all origins including shingles, post-herpetic neuralgia, diabetic neuropathy, peripheral neuropathies, intercostals neuralgia, neuralgias of the trunk and extremities.
- the present invention may be used to treat arthritis pain, osteoarthritis, rheumatoid arthritis and other arthritic conditions. It may also be used to treat sprains, strains, fibromyalgia, muscular headaches and tension type headaches.
- the term "subject” includes mammals including humans, pigs, cows, mice, rats, rabbits, goats and the like.
- the preferred subject is a human.
- the term "transdermal" composition includes compositions capable of passing through the stratum corneum of a subject.
- the term transdermal further includes compositions capable passing through the epidermis of a subject, compositions capable of passing through the dermis of a subject, and compositions capable of passing through the hydodermis of subject.
- the term transdermal includes compositions capable of passing through the skin of a subject and reaching the underlying tissues and organs.
- a transdermal composition for the relief of pain in a subject comprising: amitriptyiline, clonidine, ketamine and an anti-inflammatory in a base.
- the base may be any pharmaceutically acceptable carrier which is capable of transdermal delivery of the compounds contained within the composition. This may include a variety of finite and non-finite carriers including liquids, semi-liquids or solid carriers, such as bioadhesives.
- this may be creams, gels, emulsions, Jojions, SjalMes, .paste, .plaster, i ⁇ nsQi,- lecithins, fatty oils, lanolin, vasoline, paraffins, glycols, higher fatty acids and higher alcohols.
- Bioadhesive bases may be natural or synthetic polysaccharides. There may also be additives including binders, stabilizers, preservatives, flavorings, fiances, and pigments.
- the base may be pentravan gel. Pentravan gel is an emollient which softens and moisturizes the skin.
- Emollients may be used as lubricants to treat or prevent dry, itchy skin and minor skin irritations.
- the base may also be a base comprised of approximately 80% by weight pleurinic gel and approximately 20% by weight lipoil. The proper base is extremely important, as it acts as a vehicle that allows the various drug components to penetrate the skin. Traditional cream or ointment bases would not be effective.
- the amitriptyline may be between 2% and 4% by weight, preferably 4%. Amitriptyline is a tricyclic antidepressant with proven efficacy on neuropathic pain when administered orally. However, oral admininistration has many serious side effects, especially in the elderly population.
- This may include anticholinergic effects, such as tachycardia, dry mouth and severe sedation.
- There may be clonidine between 0.2% and 0.5% by weight, preferably 0.5%.
- Clonidine is an antihypertensive medicine.
- the composition may also have gabapentin, which may be between 5% and 15% by weight, preferably 5%.
- Gabapentin is an anticonvulsant medication.
- the ketamine may be between 5% and 20% by weight, preferably 15%. Ketamine is generally administered by IV for general anesthesia. It has NMDA inhibitor properties and is effective in controlling pain at spinal cord level.
- the anti -inflammatory may be ketoprofen between 2% and 6% by weight, preferably 5%.
- a transdermal composition for the relief of pain in a subject comprising: amitriptyiline, clonidine, gabapentin and ketamine in a base.
- the base may be pentravan gel or a composition made of 80% by weight pleurinic gel and 20% by weight lipoil.
- the composition may also comprise 5% to 10% by weight lidocaine.
- There may also be EMLA.
- EMUA is- a local anesthetic . usually used, to numb the skin tg gain, from injections. It is also sometimes used to reduce pain associated with tattooing, electrolysis, laser hair removal, etc. It is generally comprised of lidocaine and prilocaine.
- the amitriptyline may be 2% to 4% by weight
- clonidine may be 0.2% to 0.5% by weight
- gabapentin may be 6% to 12% by weight
- the ketamine may be 1 % to 20% by weight.
- an order for 60 grams of neuropathy cream may be prepared by obtaining 1.2 grams amitriptyline (2% by weight), 120 mg clonidine (0.2% by weight), 9 grams gabapentin (15% by weight) 3.6 grams ketamine (6% by weight), and 4.2 grams EMLA cream (7% by weight).
- the powders may be mixed (e.g. in an EMP Jar) and dissolved with a small amount of grain alcohol ( ⁇ 90% ethanol). Pentravan Gel may be added to make 60 grams. Finally and unguator is used to mix the final product into a very fine, smooth creme.
- a transdermal composition for the relief of pain in a subject comprising: amitriptyiline, cyclobenzaprine, dexamethazone, gabapentin and an anti-inflammatory in a base.
- the base is may be pentravan gel or a base made of 80% by weight pleurinic gel and 20% by weight lipoil.
- the amitriptyiline may be between 2% and 4% by weight
- the cyclobenzaprine may be between 2% and 4% by weight
- the dexamethazone may be between 0.2% and 0.5% by weight
- the gabapentin may be between 6% and 12% by weight.
- the anti-inflammatory may be ibuprofen being between 18% and 22% by weight.
- the anti ⁇ inflammatory may also be ketoprofen being between 2% and 4% by weight.
- Another embodiment provides a transdermal composition for the relief of pain in a subject comprising: amitriptyline, cyclobenzaprine, dexamethazone, gabapentin, an anti-inflammatory and a local anesthetic in a base.
- the base may be pentravan gel or a base made of 80% by weight pleurinic gel and 20% by weight lipoil.
- the amitriptyline may be between 2% and 4% by weight, the cyclobenzaprine may between 1% and 3% by weight, preferably, 2%, th&Mexams ⁇ xamm may .be. betoeej] 0.3% and.05% by weight, preferably 0.4%.
- the gabapentin may be between 6% and 12% by weight.
- the anti-inflammatory may be between 15% by weight and 22% by weight ibuprofen, preferably 20% by weight.
- the anti-inflammatory may also be ketoprofen between 2% by weight and 4% by weight.
- the local anesthetic may be between 5% by weight and 10% by weight lidocaine. Lidocaine is generally used in injectable form for local, regional and neuroaxial anesthesia.
- Lidocaine has been used as a topical agent, it has limited benefit when used as a sole agent.
- the local anesthetic may also be between 5% by weight and 10% by weight EMLA, preferably 7% by weight.
- EMLA is a cream, and is no longer readily available. However, the term is intended to denote a cream that has 2.5% ⁇ docaine and 2.5% Prilocaine.
- a transdermal composition for the relief of pain in a subject comprising: analgesic, an anti-epileptic compound, cyclobenzaprine, gabapentin, ketamine and an local anesthetic in a base.
- the analgesic may be between 3% and 6% by weight aspirin, preferably 5% by weight.
- the anti-epileptic may be between 2% and 4% by weight carbamazepine.
- Carbamazepine is a mood stabilizing medication, which may be sold under a variety of trade names including Tegretol.
- Carbamazepine is frequently used in psychiatric practice as either augmentation medications (to render antidepressants more effective) or as anti-manic medications in the treatment of bipolar mood disorder.
- Mood stabilizing medications are also used in neurologic practice for the treatment of seizure disorders and for the treatment of certain pain disorders.
- the gabapentin is preferably between 6% and 12% by weight, the ketamine is between 13% and 16% by weight, preferably 15%.
- the local anesthetic may be between 5% and 10% by weight lidocaine.
- a transdermal composition for the relief of pain in a subject comprising: clonidine, gabapentin, ketamin ⁇ i antiinflammatory andaa lc-cal aEislbMis in,..! . base, TM ⁇ lr ⁇ MM may be between 0.2% and 0.5% by weight, the gabapentin may be between 6% and 12% by weight, the ketamine may be between 13% and 16% by weight.
- the anti-inflammatory may be 2% to 4% by weight ketoprofen.
- the local anesthetic may be 5% to 10% by weight lidocaine or 6% to 8% by weight EMLA, preferably 7% by weight EMLA.
- a transdermal composition for the relief of pain in a subject comprising: amitriptyline, gabapentin, ketamine, anti-inflammatory and an local anesthetic in a base.
- the amitriptyline may be between 2% and 4% by weight
- gabapentin may be between 6% and 12% by weight
- ketamine may be between 13% and 16% by weight.
- the anti-inflammatory may be 2% to 4% by weight ketoprofen.
- the local anesthetic may be 5% to 10% by weight lidocaine or 6% to 8%, preferably 7% by weight, EMLA.
- a transdermal composition for the relief of pain in a subject comprising: 4% by weight amitriptyiline, 0.5% by weight clonidine, 15% by weight ketamine, and 5% by weight ketoprofen in a base.
- This composition may be further comprised of 5% by weight gabapentin.
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
PCT/US2004/020449 WO2006022611A2 (fr) | 2004-06-26 | 2004-06-26 | Creme neuropathique |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
PCT/US2004/020449 WO2006022611A2 (fr) | 2004-06-26 | 2004-06-26 | Creme neuropathique |
Publications (2)
Publication Number | Publication Date |
---|---|
WO2006022611A2 true WO2006022611A2 (fr) | 2006-03-02 |
WO2006022611A3 WO2006022611A3 (fr) | 2007-02-22 |
Family
ID=35967937
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/US2004/020449 WO2006022611A2 (fr) | 2004-06-26 | 2004-06-26 | Creme neuropathique |
Country Status (1)
Country | Link |
---|---|
WO (1) | WO2006022611A2 (fr) |
Cited By (20)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US8231891B2 (en) | 2009-07-31 | 2012-07-31 | Warsaw Orthopedic, Inc. | Implantable drug depot for weight control |
US8470360B2 (en) | 2008-04-18 | 2013-06-25 | Warsaw Orthopedic, Inc. | Drug depots having different release profiles for reducing, preventing or treating pain and inflammation |
US8557273B2 (en) | 2008-04-18 | 2013-10-15 | Medtronic, Inc. | Medical devices and methods including polymers having biologically active agents therein |
US8617583B2 (en) | 2009-07-17 | 2013-12-31 | Warsaw Orthopedic, Inc. | Alpha adrenergic receptor agonists for prevention or treatment of a hematoma, edema, and/or deep vein thrombosis |
US8629172B2 (en) | 2008-04-18 | 2014-01-14 | Warsaw Orthopedic, Inc. | Methods and compositions for treating post-operative pain comprising clonidine |
US8722079B2 (en) | 2008-04-18 | 2014-05-13 | Warsaw Orthopedic, Inc. | Methods for treating conditions such as dystonia and post-stroke spasticity with clonidine |
ES2484068A1 (es) * | 2013-02-08 | 2014-08-08 | Ana MÍNGUEZ MARTÍ | Una composición farmacéutica que contiene ketamina y amitriptilina |
US8822546B2 (en) | 2008-12-01 | 2014-09-02 | Medtronic, Inc. | Flowable pharmaceutical depot |
US8889173B2 (en) | 2008-04-18 | 2014-11-18 | Warsaw Orthopedic, Inc. | Alpha adrenergic receptor agonists for treatment of pain and/or inflammation |
US8946277B2 (en) | 2008-04-18 | 2015-02-03 | Warsaw Orthopedic, Inc. | Clonidine formulations in a biodegradable polymer carrier |
US8956641B2 (en) | 2008-04-18 | 2015-02-17 | Warsaw Orthopedic, Inc. | Alpha adrenergic receptor agonists for treatment of inflammatory diseases |
US9072727B2 (en) | 2008-04-18 | 2015-07-07 | Warsaw Orthopedic, Inc. | Alpha adrenergic receptor agonists for treatment of degenerative disc disease |
US9132119B2 (en) | 2008-04-18 | 2015-09-15 | Medtronic, Inc. | Clonidine formulation in a polyorthoester carrier |
US9132085B2 (en) | 2008-04-18 | 2015-09-15 | Warsaw Orthopedic, Inc. | Compositions and methods for treating post-operative pain using clonidine and bupivacaine |
US9358223B2 (en) | 2009-10-26 | 2016-06-07 | Warsaw Orthopedic, Inc. | Formulation for preventing or reducing bleeding at a surgical site |
US9492461B2 (en) | 2008-04-18 | 2016-11-15 | Warsaw Orthopedic, Inc. | Methods and compositions for treating intervertebral disc herniations |
US9610243B2 (en) | 2008-04-18 | 2017-04-04 | Warsaw Orthopedic, Inc. | Clonidine compounds in a biodegradable polymer |
US10653619B2 (en) | 2009-03-23 | 2020-05-19 | Medtronic, Inc. | Drug depots for treatment of pain and inflammation |
WO2021255522A1 (fr) * | 2020-06-19 | 2021-12-23 | Guangzhou Dazhou Biomedicine Ltd. | Système d'administration transdermique de médicament pour kétamine |
USRE48948E1 (en) | 2008-04-18 | 2022-03-01 | Warsaw Orthopedic, Inc. | Clonidine compounds in a biodegradable polymer |
Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20030082214A1 (en) * | 2001-08-17 | 2003-05-01 | Williams Robert O. | Topical compositions and methods for treating pain |
US6572880B2 (en) * | 1996-10-24 | 2003-06-03 | Pharmaceutical Applications Associates Llc | Methods and transdermal compositions for pain relief |
US20040101582A1 (en) * | 2002-11-25 | 2004-05-27 | Richard Wolicki | Treatment of neuropathy |
-
2004
- 2004-06-26 WO PCT/US2004/020449 patent/WO2006022611A2/fr active Application Filing
Patent Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6572880B2 (en) * | 1996-10-24 | 2003-06-03 | Pharmaceutical Applications Associates Llc | Methods and transdermal compositions for pain relief |
US20030082214A1 (en) * | 2001-08-17 | 2003-05-01 | Williams Robert O. | Topical compositions and methods for treating pain |
US20040101582A1 (en) * | 2002-11-25 | 2004-05-27 | Richard Wolicki | Treatment of neuropathy |
Cited By (32)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US9211285B2 (en) | 2008-04-18 | 2015-12-15 | Warsaw Orthopedic, Inc. | Methods and compositions for treating post-operative pain comprising clonidine |
US9585872B2 (en) | 2008-04-18 | 2017-03-07 | Warsaw Orthopedic, Inc. | Clonidine formulations in a biodegradable polymer carrier |
US8557273B2 (en) | 2008-04-18 | 2013-10-15 | Medtronic, Inc. | Medical devices and methods including polymers having biologically active agents therein |
US9132119B2 (en) | 2008-04-18 | 2015-09-15 | Medtronic, Inc. | Clonidine formulation in a polyorthoester carrier |
US8629172B2 (en) | 2008-04-18 | 2014-01-14 | Warsaw Orthopedic, Inc. | Methods and compositions for treating post-operative pain comprising clonidine |
US8722079B2 (en) | 2008-04-18 | 2014-05-13 | Warsaw Orthopedic, Inc. | Methods for treating conditions such as dystonia and post-stroke spasticity with clonidine |
USRE48948E1 (en) | 2008-04-18 | 2022-03-01 | Warsaw Orthopedic, Inc. | Clonidine compounds in a biodegradable polymer |
US9132085B2 (en) | 2008-04-18 | 2015-09-15 | Warsaw Orthopedic, Inc. | Compositions and methods for treating post-operative pain using clonidine and bupivacaine |
US8889173B2 (en) | 2008-04-18 | 2014-11-18 | Warsaw Orthopedic, Inc. | Alpha adrenergic receptor agonists for treatment of pain and/or inflammation |
US8946277B2 (en) | 2008-04-18 | 2015-02-03 | Warsaw Orthopedic, Inc. | Clonidine formulations in a biodegradable polymer carrier |
US8956641B2 (en) | 2008-04-18 | 2015-02-17 | Warsaw Orthopedic, Inc. | Alpha adrenergic receptor agonists for treatment of inflammatory diseases |
US8968767B2 (en) | 2008-04-18 | 2015-03-03 | Warsaw Orthopedic, Inc. | Drug depots having different release profiles for reducing, preventing or treating pain and inflammation |
US8999368B2 (en) | 2008-04-18 | 2015-04-07 | Warsaw Orthopedic, Inc. | Medical devices and methods including polymers having biologically active agents therein |
US9072727B2 (en) | 2008-04-18 | 2015-07-07 | Warsaw Orthopedic, Inc. | Alpha adrenergic receptor agonists for treatment of degenerative disc disease |
US9833548B2 (en) | 2008-04-18 | 2017-12-05 | Warsaw Orthopedic, Inc. | Methods and compositions for treating post-operative pain comprising clonidine |
US9775800B2 (en) | 2008-04-18 | 2017-10-03 | Warsaw Orthopedic, Inc. | Compositions and methods for treating post-operative pain using clonidine and bupivacaine |
US9770438B2 (en) | 2008-04-18 | 2017-09-26 | Warsaw Orthopedic, Inc. | Clonidine formulation in a polyorthoester carrier |
US9265733B2 (en) | 2008-04-18 | 2016-02-23 | Warsaw Orthopedic, Inc. | Drug depots having different release profiles for reducing, preventing or treating pain and inflammation |
US9351959B2 (en) | 2008-04-18 | 2016-05-31 | Warsaw Orthopedic, Inc. | Alpha adreneric receptor agonists for treatment of degenerative disc disease |
US9763917B2 (en) | 2008-04-18 | 2017-09-19 | Warsaw Orthopedic, Inc. | Clonidine formulations in a biodegradable polymer carrier |
US9387197B2 (en) | 2008-04-18 | 2016-07-12 | Warsaw Orthopedic, Inc. | Methods for treating conditions such as dystonia and post-stroke spasticity with clonidine |
US9492461B2 (en) | 2008-04-18 | 2016-11-15 | Warsaw Orthopedic, Inc. | Methods and compositions for treating intervertebral disc herniations |
US8470360B2 (en) | 2008-04-18 | 2013-06-25 | Warsaw Orthopedic, Inc. | Drug depots having different release profiles for reducing, preventing or treating pain and inflammation |
US9610243B2 (en) | 2008-04-18 | 2017-04-04 | Warsaw Orthopedic, Inc. | Clonidine compounds in a biodegradable polymer |
US8822546B2 (en) | 2008-12-01 | 2014-09-02 | Medtronic, Inc. | Flowable pharmaceutical depot |
US10653619B2 (en) | 2009-03-23 | 2020-05-19 | Medtronic, Inc. | Drug depots for treatment of pain and inflammation |
US8617583B2 (en) | 2009-07-17 | 2013-12-31 | Warsaw Orthopedic, Inc. | Alpha adrenergic receptor agonists for prevention or treatment of a hematoma, edema, and/or deep vein thrombosis |
US8231891B2 (en) | 2009-07-31 | 2012-07-31 | Warsaw Orthopedic, Inc. | Implantable drug depot for weight control |
US9358223B2 (en) | 2009-10-26 | 2016-06-07 | Warsaw Orthopedic, Inc. | Formulation for preventing or reducing bleeding at a surgical site |
ES2484068A1 (es) * | 2013-02-08 | 2014-08-08 | Ana MÍNGUEZ MARTÍ | Una composición farmacéutica que contiene ketamina y amitriptilina |
WO2021255522A1 (fr) * | 2020-06-19 | 2021-12-23 | Guangzhou Dazhou Biomedicine Ltd. | Système d'administration transdermique de médicament pour kétamine |
US11559497B2 (en) | 2020-06-19 | 2023-01-24 | Guangzhou Dazhou Biomedicine Ltd. | Transdermal drug delivery system for ketamine |
Also Published As
Publication number | Publication date |
---|---|
WO2006022611A3 (fr) | 2007-02-22 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US20040265364A1 (en) | Neuropathy cream | |
US20080171075A1 (en) | Neuropathy cream | |
WO2006022611A2 (fr) | Creme neuropathique | |
US11517546B2 (en) | High concentration local anesthetic formulations | |
US5994330A (en) | Topical application of muscarinic agents such as neostigmine for treatment of acne and other inflammatory conditions | |
US8211887B2 (en) | Topical preparation and method for transdermal delivery and localization of therapeutic agents | |
US5885597A (en) | Topical composition for the relief of pain | |
US20040202722A1 (en) | Alcohol-free transdermal analgesic composition and processes for manufacture and use thereof | |
US6143278A (en) | Topical application of opioid analgesic drugs such as morphine | |
CN106572970B (zh) | 用于局部给药非甾体抗炎药以缓解肌肉骨骼疼痛的新型凝胶及其制备方法 | |
US6894078B2 (en) | Alcohol based topical anesthetic formulation and method | |
UA125040C2 (uk) | Фенітоїн для місцевого застосування для використання при лікуванні периферичного нейропатичного болю | |
US20100041704A1 (en) | Dermal compositions of substituted amides and the use thereof as medication for pain and pruritus | |
Fransson et al. | Transdermal absorption of a liposomeencapsulated formulation of lidocaine following topical administration in cats | |
US20090137628A1 (en) | Formulations of Indanylamines and the Use Thereof as Local Anesthetics and as Medication for Chronic Pain | |
US6011022A (en) | Topical application of muscarinic analgesic drugs such as neostigmine | |
US11571421B2 (en) | GABAA positive allosteric modulator compounds for treatment of itch and/or dermatitis | |
Cantisani et al. | New patents on topical anesthetics | |
WO2009061298A1 (fr) | Traitement topique avec le dapsone chez des patients déficients en g6pd | |
JP2024507011A (ja) | エマルション組成物、ならびに放射線によって引き起こされる皮膚損傷の予防および/または処置におけるその使用 | |
BRPI0621416A2 (pt) | composição para o tratamento de doenças bacterianas, virais, fúngicas, inflamação e dor | |
Kuczyńska et al. | New studies on dexketoprofen | |
US20110218218A1 (en) | Formulations Of Indanylamines And The Use Thereof As Local Anesthetics And As Medication For Chronic Pain | |
US20060263439A1 (en) | Alcohol-free transdermal analgesic composition and processes for manufacture and use thereof | |
JP2002060349A (ja) | 皮膚外用剤 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AK | Designated states |
Kind code of ref document: A2 Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BW BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NA NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW |
|
AL | Designated countries for regional patents |
Kind code of ref document: A2 Designated state(s): GM KE LS MW MZ NA SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LU MC NL PL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG |
|
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
NENP | Non-entry into the national phase in: |
Ref country code: DE |
|
WWW | Wipo information: withdrawn in national office |
Country of ref document: DE |
|
122 | Ep: pct application non-entry in european phase |